Prognostic Factors and Progression Biomarkers in AL Amyloidosis: Mapping Current Knowledge and Critical Gaps The therapeutic landscape for systemic immunoglobulin light chain (AL) amyloidosis has been revolutionized by daratumumab-based regimens, achieving 76% fiv

The #AmyloidosisForum Prognostic Factors working group just published a new review in Blood on prognostic factors and progression biomarkers in #AL #amyloidosis, as well as the critical need for updated validation studies.

Read the review: doi.org/10.1182/bloo...

2025 Amyloidosis Forum Annual Meeting This meeting detailed the Amyloidosis Forum working groups' projects to accelerate drug development in AL and ATTR Amyloidosis

The 2025 annual #AmyloidosisForum was the most well attended meeting yet.

Discussions covered:
• Current Challenges & Innovative Solutions
• Imaging Standardization
• Prognostic Factors
• Endpoint Development

Watch the recordings here: amyloidosisforum.org/2025-meeting...

Good morning! Are you ready to hear from clinicians, drug developers, and regulatory members discuss the most important topics facing #amyloidosis?

Tune in to the #AmyloidosisForum online any time between 8-4 today for some important conversations! amyloidosisforum.org/2025-meeting/